Home›Fluoroestradiol F 18›Fluoroestradiol F 18 + Elacestrant

Does Fluoroestradiol F 18 Interact with Elacestrant?

Fluoroestradiol F 18 and Elacestrant have a major drug interaction according to U.S. FDA drug labeling data. Binds to estrogen receptor and competes with fluoroestradiol F 18, reducing detection of ER-positive lesions. Discontinue for at least 11 days before administering CERIANNA. The mechanism involves competition for estrogen receptor binding. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Fluoroestradiol F 18 Class
Radioactive Diagnostic Agent
Elacestrant Class
Estrogen Receptor Antagonist
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Fluoroestradiol F 18 and Elacestrant occurs because competition for estrogen receptor binding. Clinically, this means binds to estrogen receptor and competes with fluoroestradiol f 18, reducing detection of er-positive lesions. discontinue for at least 11 days before administering cerianna. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Fluoroestradiol F 18 and your doctor is considering prescribing Elacestrant (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Fluoroestradiol F 18(Cerianna)+💊 Elacestrant(Orserdu)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Radioactive Diagnostic Agent
Drug B class
Estrogen Receptor Antagonist
Source
NLP:fluoroestradiol f 18

What this means in plain English

Binds to estrogen receptor and competes with fluoroestradiol F 18, reducing detection of ER-positive lesions. Discontinue for at least 11 days before administering CERIANNA.

What the FDA label says

"Competition for estrogen receptor binding"

📖 Source: NLP:fluoroestradiol f 18

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Fluoroestradiol F 18 and Elacestrant against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.